a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced it will hold an investor conference call on Friday, August 22 at 2:00 pm ET.
During the call, Andrew Morris, CEO, will provide a brief review of SQI’s recent commercialization progress and then introduce Dr. Allan Pronovost, a diagnostics industry veteran recently appointed to the Board of Directors of SQI and also as a Strategic Advisor to the Board. Dr. Pronovost will comment on the Company and the diagnostics industry from his perspective. The call will conclude with Mr. Morris and Dr. Pronovost responding to any questions from the investment community, which can be submitted prior to the call by email to IR@sqidiagnostics.com.
To access the conference call, dial 647-427-7450 or 1-888-231-8191 or go to http://www.newswire.ca/en/webcast/detail/1399518/1553736 or www.sqidiagnostics.com. An archived replay of the webcast will be available through www.sqidiagnostics.com.
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company’s proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit www.sqidiagnostics.com.
Investor Relations Contact:
Chief Executive Officer
416.674.9500 ext. 229
VP Corporate Development
416.674.9500 ext. 241
This news release contains certain forward-looking statements, including, without limitation, statements containing the words “will”, “expects”, “intends” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to risks related to the failure to obtain necessary regulatory approvals, general economic and market segment conditions, and international risk and currency exchange, agreements and future agreements to sell our products, the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business, the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits, the acceleration of our revenue ramp, general economic and market segment conditions, competitor activity, technology changes and regulatory approvals. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.